Oral APX3330 outperformed placebo in slowing progression of diabetic retinopathy in the phase 2 ZETA-1 trial, according to results presented by Ocuphire Pharma at the virtual Angiogenesis, Exudation and Degeneration 2024 conference.
“Diabetic retinopathy affects millions of Americans and is a disease we see every day in our clinics,” Veeral Sheth, MD, MBA, FACS, FASRS, partner and director of clinical trials at University Retina and clinical assistant professor at the University of Illinois at Chicago, told Healio. “We know that without intervention, many of these patients